Michael Andriole
Chief Executive Officer presso CHIMERIX, INC.
Patrimonio netto: 473 842 $ in data 31/03/2024
Profilo
Michael T.
Andriole is currently the President, Chief Executive Officer & Director at Chimerix, Inc. Prior to his current position, he served as the Vice President-Corporate Business Development at Eli Lilly & Co. from 2014 to 2017.
He also worked as the Chief Financial Officer at Endocyte, Inc. in 2017 and 2018.
Mr. Andriole holds an MBA from Kelley School of Business and an undergraduate degree from Williams College of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CHIMERIX, INC.
0.50% | 14/02/2024 | 447 021 ( 0.50% ) | 473 842 $ | 31/03/2024 |
Posizioni attive di Michael Andriole
| Società | Posizione | Inizio |
|---|---|---|
| CHIMERIX, INC. | Chief Executive Officer | 01/08/2023 |
Precedenti posizioni note di Michael Andriole
| Società | Posizione | Fine |
|---|---|---|
| ENDOCYTE, INC. | Director of Finance/CFO | 01/12/2018 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/02/2017 |
Formazione di Michael Andriole
| Kelley School of Business | Masters Business Admin |
| Williams College of Business | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CHIMERIX, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
- Borsa valori
- Insiders
- Michael Andriole
